GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allergan, Inc. (AGN) [hlAlert]

Rating:
Overweight
AGN
up 583.90 %

Allergan, Inc. (AGN) rated Overweight with price target $54 by Thomas Weisel

Posted on: Tuesday,  Jun 2, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Allergan, Inc. (NYSE: AGN) on 06/02/2009, when the stock price was $44.74. Since
then, Allergan, Inc. has gained 583.91% as of 11/24/2015's recent price of $305.98.
If you would have followed this Thomas Weisel's recommendation on AGN, you would have gained 583.9% of your investment in 2366 days.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/2/2009 8:25 AM Buy
None
44.74 54.00
as of 12/31/2009
1 Week up  13.92 %
1 Month up  22.75 %
3 Months up  25.72 %
1 YTD up  59.49 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy